Arena Pharmaceuticals Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/8/2022)
| Balance Sheet | Total Assets | 784,705,000.00 | ROE | – |
| Balance Sheet | Total Equity | 120,846,033.71 | ROA | – |
| Cashflow | Capital Expenditures | -988,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -453,004,000.00 | – | – |
| Cashflow | Operating Cash Flow | -452,016,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -10.14 | Div. Yield | – |
| Income | Net Income | -616,433,000.00 | P/E | – |
| Income | Shares Outstanding | 60,776,000.00 | P/B | – |
| Income | Total Revenue | 54,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company´s oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, which is in Phase I; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases, and APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain, which is in preclinical development. In June 2012, the United States Food and Drug Administration approved its internally discovered drug, BELVIQ.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.arenapharm.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more